These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6923744)

  • 41. Two enteric coated microspheres in cystic fibrosis.
    Williams J; MacDonald A; Weller PH; Fields J; Pandov H
    Arch Dis Child; 1990 Jun; 65(6):594-7. PubMed ID: 2198848
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pancreatic enzyme replacement therapy in post-pancreatectomy patients.
    Braga M; Cristallo M; De Franchis R; Mangiagalli A; Zerbi A; Agape D; Primignani M; Di Carlo V
    Int J Pancreatol; 1989; 5 Suppl():37-44. PubMed ID: 2702249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
    Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
    J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of pancreatic Schilling test to determine efficiency of pancreatic enzyme delivery in pancreatic insufficiency.
    Brugge WR; Goldberg HJ; Burke CA; Depping BJ
    Dig Dis Sci; 1988 Oct; 33(10):1226-32. PubMed ID: 3168695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of distal intestinal obstruction syndrome in cystic fibrosis.
    Rosenstein BJ; Langbaum TS
    J Pediatr Gastroenterol Nutr; 1983 May; 2(2):299-301. PubMed ID: 6553601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and safety of small vs. large doses of enteric coated pancreatic enzymes in reducing steatorrhea in children with cystic fibrosis: a prospective randomized study.
    Brady MS; Rickard K; Yu PL; Eigen H
    Pediatr Pulmonol; 1991; 10(2):79-85. PubMed ID: 2030925
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in cystic fibrosis.
    Winklhofer-Roob BM; Tiran B; Tuchschmid PE; van't Hof MA; Shmerling DH
    Free Radic Biol Med; 1998 Jul; 25(2):242-9. PubMed ID: 9667502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis.
    Santini B; Antonelli M; Battistini A; Bertasi S; Collura M; Esposito I; Di Febbraro L; Ferrari R; Ferrero L; Iapichino L; Lucidi V; Manca A; Pisconti CL; Pisi G; Raia V; Romano L; Rosati P; Grazioli I; Melzi G
    Dig Liver Dis; 2000; 32(5):406-11. PubMed ID: 11030186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lack of dose-response with Pancrease MT for the treatment of exocrine pancreatic insufficiency in adults.
    Opekun AR; Sutton FM; Graham DY
    Aliment Pharmacol Ther; 1997 Oct; 11(5):981-6. PubMed ID: 9354210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medical treatment of pancreatic insufficiency.
    DiMagno EP
    Mayo Clin Proc; 1979 Jul; 54(7):435-42. PubMed ID: 36518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis.
    Kalnins D; Ellis L; Corey M; Pencharz PB; Stewart C; Tullis E; Durie PR
    J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):256-61. PubMed ID: 16540792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency.
    Regan PT; Malagelada JR; DiMagno EP; Glanzman SL; Go VL
    N Engl J Med; 1977 Oct; 297(16):854-8. PubMed ID: 20572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis.
    Morrison G; Morrison JM; Redmond AO; Byers CA; McCracken KJ; Dodge JA; Guilford SA; Bowden MW
    Aliment Pharmacol Ther; 1992 Oct; 6(5):549-55. PubMed ID: 1420747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
    Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
    Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzyme replacement therapy of exocrine pancreatic insufficiency in man. Relations between in vitro enzyme activities and in vivo potency in commercial pancreatic extracts.
    Graham DY
    N Engl J Med; 1977 Jun; 296(23):1314-7. PubMed ID: 16212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Solubility of oral pancreatic enzyme supplement capsules in biological fluids.
    Robb TS; Davidson GP; Cooper DM
    Lancet; 1980 Sep; 2(8193):544. PubMed ID: 6105599
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity.
    Hendeles L; Dorf A; Stecenko A; Weinberger M
    JAMA; 1990 May; 263(18):2459-61. PubMed ID: 2329633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fibrosing colonopathy in children with cystic fibrosis.
    Postgrad Med J; 1996 Mar; 72 Suppl 2():S11-29. PubMed ID: 8869179
    [No Abstract]   [Full Text] [Related]  

  • 59. The ins and outs of oral pancreatic enzymes.
    Meyer JH
    N Engl J Med; 1977 Jun; 296(23):1347-8. PubMed ID: 859534
    [No Abstract]   [Full Text] [Related]  

  • 60. Pancreatic extracts.
    Br Med J; 1970 Apr; 2(5702):161-3. PubMed ID: 5440600
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.